Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Starting in September, the UK’s new RSV vaccine program will offer protection across all age groups — find out what this ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Vicebio has recently initiated a Phase I clinical trial with VXB-241, its bivalent vaccine targeting both RSV and hMPV viruses that cause a significant burden of disease in elderly patients and those ...

October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.

The Respiratory Syncytial Virus (RSV) vaccine will be rolled out to some older islanders as well as pregnant women. | ITV ...